EIF4E and cancer: Since many cancers overwhelm the inhibitory capacity of 4E-BP1 by downregulating 4E-BP1 and/or upregulating eIF4E (1, 10, 11), the finding that SMAPs increase 4E-BP1 levels points to the promise of these agents for restoring the 4E-BP1/eIF4E ratio for translational control in a broad spectrum of cancer types.